| Medical and Health Sciences | Lifetime | 757 | US 390 | 99.97 |
| Medical and Health Sciences | 2021-2025 | 54 | US 25 | 99.99 |
| Cardiology and Cardiovascular Medicine | Lifetime | 97 | US 54 | 99.91 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 149 | US 83 | 99.54 |
| Hematology | Lifetime | 905 | US 445 | 90.69 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 20 | US 12 | 99.91 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 16 | US 11 | 99.89 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 393 | US 125 | 95.95 |
| Surgery | 2021-2025 | 729 | US 279 | 93.62 |
| Heart Failure Treatment and Management | Lifetime | 13 | US 8 | 99.94 |
| Cardiovascular Function and Risk Factors | Lifetime | 62 | US 45 | 99.88 |
| Electrolyte and hormonal disorders | Lifetime | 22 | US 12 | 99.47 |
| Hormonal Regulation and Hypertension | Lifetime | 69 | US 31 | 99.51 |
| Diabetes Treatment and Management | Lifetime | 86 | US 40 | 99.57 |
| Cardiac pacing and defibrillation studies | Lifetime | 109 | US 58 | 99.56 |
| Potassium and Related Disorders | Lifetime | 31 | US 21 | 99.29 |
| Mechanical Circulatory Support Devices | Lifetime | 206 | US 125 | 98.97 |
| Erythropoietin and Anemia Treatment | Lifetime | 65 | US 28 | 98.65 |
| Cardiac Structural Anomalies and Repair | Lifetime | 382 | US 246 | 98.83 |
| Atrial Fibrillation Management and Outcomes | Lifetime | 615 | US 246 | 98.54 |
| Cardiac Arrest and Resuscitation | Lifetime | 676 | US 364 | 98.27 |
| Blood Pressure and Hypertension Studies | Lifetime | 764 | US 309 | 97.91 |
| GDF15 and Related Biomarkers | Lifetime | 67 | US 27 | 95.18 |
| Iron Metabolism and Disorders | Lifetime | 523 | US 236 | 96.97 |
| Cardiac Fibrosis and Remodeling | Lifetime | 662 | US 241 | 92.37 |
| Heart rate and cardiovascular health | Lifetime | 347 | US 108 | 82.28 |
| Electrolyte and hormonal disorders | 2021-2025 | 1 | US 1 | 99.69 |
| Hormonal Regulation and Hypertension | 2021-2025 | 3 | US 3 | 99.86 |
| Heart Failure Treatment and Management | 2021-2025 | 12 | US 8 | 99.89 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 38 | US 20 | 99.73 |
| Diabetes Treatment and Management | 2021-2025 | 30 | US 18 | 99.71 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 27 | US 11 | 99.46 |
| Pancreatic function and diabetes | 2021-2025 | 88 | US 49 | 97.95 |
| Potassium and Related Disorders | 2021-2025 | 22 | US 11 | 97.88 |
| Cardiac pacing and defibrillation studies | 2021-2025 | 233 | US 92 | 97.18 |
| Erythropoietin and Anemia Treatment | 2021-2025 | 40 | US 14 | 95.17 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 181 | US 54 | 94.23 |
| Atrial Fibrillation Management and Outcomes | 2021-2025 | 582 | US 151 | 96.00 |
| Diet and metabolism studies | 2021-2025 | 913 | US 272 | 92.45 |
| Cardiac Structural Anomalies and Repair | 2021-2025 | 780 | US 348 | 92.13 |
| Iron Metabolism and Disorders | 2021-2025 | 414 | US 151 | 88.54 |
| Renal function and acid-base balance | 2021-2025 | 129 | US 43 | 82.82 |
| Chemotherapy-induced cardiotoxicity and mitigation | 2021-2025 | 501 | US 144 | 77.95 |
| GDF15 and Related Biomarkers | 2021-2025 | 208 | US 59 | 73.84 |
| Cardiac Fibrosis and Remodeling | 2021-2025 | 650 | US 154 | 68.76 |
| Medication Adherence and Compliance | 2021-2025 | 985 | US 330 | 67.73 |
| Heart rate and cardiovascular health | 2021-2025 | 105 | US 27 | 61.21 |
| Signaling Pathways in Disease | 2021-2025 | 761 | US 172 | 52.00 |
